Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06116110 · ClinicalTrials.gov registry record
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
A clinical trial of Non-Hodgkin Lymphoma, sponsored by Miltenyi Biomedicine.
- Recruiting
- Registry status
- 150
- Enrollment target
- 5
- Study locations
NCT06116110: Recruiting study of Non-Hodgkin Lymphoma, sponsored by Miltenyi Biomedicine.
NCT06116110 is a study of Non-Hodgkin Lymphoma that is actively recruiting participants, run by Miltenyi Biomedicine. The registered enrollment target is 150 participants, below the 166-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (10% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06116110, a study of Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Miltenyi Biomedicine.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Conditions Studied
Interventions
- OTHER Long-term Follow-Up
Study Locations (5)
California
- Stanford University - Stanford
Connecticut
- Yale University - New Haven
Maryland
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Wisconsin
- Froedtert Hospital and the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2039-12-01 |
What NCT06116110 shows while recruiting
NCT06116110 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 166-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Long-term Follow-Up is the first listed.
NCT06116110 lists 5 locations in 5 states (California, Connecticut, Maryland).
Frequently Asked Questions
What is clinical trial NCT06116110 about?
NCT06116110 is a clinical study titled "Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU". This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
What is the current status of trial NCT06116110?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-05-15. Estimated completion is 2039-12-01.
What conditions does trial NCT06116110 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06116110?
The interventions under investigation include: Long-term Follow-Up (OTHER).
Who is sponsoring clinical trial NCT06116110?
This trial is sponsored by Miltenyi Biomedicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06116110 being conducted?
This trial has 5 study locations across California, Connecticut, Maryland, Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06116110's enrollment target sits among peer trials
150 26th of 106 higher than 80 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
RECRUITING · Early Phase 1
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI